SavedAdd your journal

Journals / Online Türk Sağlık Bilimleri Dergisi / 2022 / Cilt: 7 Sayı: 4

Non-Fermenting Gram-Negative Isolates as Infecting Agents and Antibiotic Resistance: Three-Year Data

Enfeksiyon Etkeni Nonfermenter Gram Negatif İzolatlar ve Antibiyotik Dirençleri: Üç Yıllık Veri

Ali Korhan Sığ(Atatürk City Hospital, Department of Medical Microbiology)0000-0003-2907-257X
Alev Çetin Duran(Atatürk City Hospital, Department of Medical Microbiology)0000-0002-1681-8240
Tuğba Kula Atik(BALIKESIR UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-2433-1977
Nermin Özen(Atatürk City Hospital, Department of Medical Microbiology)0000-0002-4876-3555
Onur Irmak(Atatürk City Hospital, Department of Medical Microbiology)0000-0002-1433-1519
Pages
538–545
Publication Date
2022-12-10
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: This study aimed to investigate clinical non-fermenting gram-negative isolates and antibiotic resistance profiles for three years in a tertiary hospital.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to investigate clinical non-fermenting gram-negative isolates and antibiotic resistance profiles for three years in a tertiary hospital.
📊
Key Findings & Data:Objective: This study aimed to investigate clinical non-fermenting gram-negative isolates and antibiotic resistance profiles for three years in a tertiary hospital.
💡
Conclusion & Impact:Objective: This study aimed to investigate clinical non-fermenting gram-negative isolates and antibiotic resistance profiles for three years in a tertiary hospital.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:Acinetobacter · antimicrobial resistance · Burkholderia

Abstract

Objective: This study aimed to investigate clinical non-fermenting gram-negative isolates and antibiotic resistance profiles for three years in a tertiary hospital.

Özet

Amaç: Bu çalışmanın amacı, üç yıllık dönemde bir üçüncü basamak hastanenin enfeksiyon etkeni nonfermenter gram negatif izolatlarını ve antibiyotik direnç profillerini belirlemektir.

🔖

Cite This Article

Sığ, A. K., Duran, A. Ç., Atik, T. K., Özen, N., Irmak, O. (2022). Non-Fermenting Gram-Negative Isolates as Infecting Agents and Antibiotic Resistance: Three-Year Data. Online Türk Sağlık Bilimleri Dergisi, Cilt: 7 Sayı: 4, 538–545. https://doi.org/10.26453/otjhs.1058819

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Fuhrmeister AS, Jones RN. The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program. Open Forum Infect Dis. 2019;6(S1):S1–S4. doi:10.1093/ofid/ofy346
  2. National Antimicrobial Surveillance System. https://hsgm.saglik.gov.tr/tr/uamdss. Accessed June 17, 2021.
  3. World Health Organization (WHO). Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR), Annual 2020 Report, 2020. https://www.euro.who.int/__data/assets/pdf_file/0003/469200/Central-Asian-and-European-Surveillance-of-Antimicrobial-Resistance.-Annual-report-2020-eng.pdf. Accessed June 17, 2021.
  4. Zhanel GG, Adam HJ, Baxter MR, et al. 42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study. J Antimicrob Chemother. 2019;74(Suppl 4):iv5–iv21. doi:10.1093/jac/dkz283
  5. Lagacé-Wiens PR, Adam HJ, et al. Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007–16. J Antimicrob Chemother. 2019;74(Suppl 4):iv22–iv31. doi:10.1093/jac/dkz284
  6. European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2019. Stockholm: ECDC; 2020. https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019. Accessed June 17, 2021.
  7. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. doi:10.15620/cdc:82532. Accessed June 17, 2021.
  8. WHO priority pathogens list for R&D of new antibiotics. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed June 17, 2021.
  9. Sfeir MM. Burkholderia cepacia complex infections: more complex than the bacterium name suggest. J Infect. 2018;77(3):166-170. doi:10.1016/j.jinf.2018.07.006
  10. Adegoke AA, Stenström TA, Okoh AI. Stenotrophomonas maltophilia as an emerging ubiquitous pathogen: looking beyond contemporary antibiotic therapy. Front Microbiol. 2017;8:2276. doi:10.3389/fmicb.2017.02276
  11. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, Basel, Switzerland. https://www.eucast.org. Accessed June 17, 2021.
  12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-seventh informational supplement, M100-S27, Wayne, Pennsylvania: CLSI; 2017.
  13. Uskudar-Guclu A, Gozen AG. Genetic Diversity of OXA-like genes in multidrug resistant Acinetobacter baumannii strains from ICUs. Clin Lab. 2020;66:2015-2019. doi:10.7754/clin.lab.2020.200135
  14. Uskudar-Guclu A, Guney M, Sig AK, Kilic S, Baysallar M. Arising Prevalence of OXA-48 producer Escherichia coli and OXA-48 with NDM co-producer Klebsiella pneumoniae Strains. Rev Rom Med Lab. 2019;27(3):319-326. doi:10.2478/rrlm-2019-0030
  15. Mataj V, Guney M, Sig AK, et al. An Investigation into bacterial bloodstream infections and antibiotic resistance profiles in a tertiary hospital for a ten-year period. Clin Lab. 2020;66:1467-1477. doi:10.7754/Clin.Lab.2020.191033
  16. Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agent Chemother. 2019;63(7):e00355-19. doi:10.1128/AAC.00355-19
  17. Gales AC, Castanheira M, Seifert H, Gur D, Jones RN, Sader HS. The Worldwide Panorama of Acinetobacter baumannii Group and Stenotrophomonas maltophilia in the Last 20 Years: Results from the SENTRY Antimicrobial Surveillance Program (1997–2016). In: The 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2018. https://www.jmilabs.com/data/posters/ECCMID2018-SENTRY-Acinetobacter.pdf. Accessed June 17, 2021.
  18. Uskudar-Guclu A, Altay-Kocak A, Akcil-Ok M, Tutluoglu B, Basustaoglu AC, Respiratory Study Group. Antibacterial Resistance in Lower Respiratory Tract Bacterial Pathogens: A Multicenter Analysis from Turkey. J Infect Dev Ctries. 2021;15(2):254-262. doi:10.3855/jidc.12599.
  19. The European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption and resistance in bacteria from humans and animals: Inter-agency Report, 2016-2018. https://www.ecdc.europa.eu/sites/default/files/documents/JIACRA-III-Antimicrobial-Consumption-and-Resistance-in-Bacteria-from-Humans-and-Animals.pdf. Accessed June 17, 2021.
  20. Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TLY, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect. 2012;45(2):120-126. doi:10.1016/j.jmii.2011.09.028
  21. Matson HH, Jones BM, Wagner JL, Motes MA, Bland CM. Growing resistance in Stenotrophomonas maltophilia?. Am J Health Syst Pharm. 2019;76(24):2004-2005. doi:10.1093/ajhp/zxz247
  22. Cusack TP, Ashley EA, Ling CL, et al. Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance. Clin Microb Infect. 2019;25(7):910-911. doi:10.1016/j.cmi.2019.03.007
  23. Satlin MJ. The search for a practical method for colistin susceptibility testing: Have we found it by going back to the future?. J Clin Microb. 2019;57(2):e01608-18. doi:10.1128/JCM.01608-18